Cadrenal Therapeutics(US:CVKD)2026-03-31 12:55Financial Performance - Cadrenal reported a net loss of $3.0 million for Q4 2025, a decrease from $4.2 million in Q4 2024, reflecting a 29% improvement year-over-year[5] - General and administrative expenses for Q4 2025 were $2.4 million, compared to $2.7 million in Q4 2024, a decrease of approximately 11%[5] - Total operating expenses for the year ended December 31, 2025, were $13.5 million, an increase from $11.0 million in 2024, representing a 23% rise[15] - The company’s accumulated deficit increased to $38.96 million as of December 31, 2025, compared to $25.72 million at the end of 2024[13] - The company had cash and cash equivalents of $4.0 million as of December 31, 2025, down from $10.0 million at the end of 2024[6] Research and Development - Research and development expenses for Q4 2025 were $0.7 million, down from $1.5 million in Q4 2024, indicating a 53% reduction[5] - CAD-1005 demonstrated a greater than 25% absolute reduction in thrombotic events compared to placebo in a Phase 2 study[4] - The End-of-Phase 2 meeting with the FDA on March 26, 2026, clarified the regulatory path for the planned Phase 3 trial of CAD-1005[4] - CAD-1005 is positioned as the only selective 12-LOX inhibitor in clinical development, supported by Orphan Drug and Fast Track designations from the FDA[4] - The company continues to explore longer-term opportunities across its broader 12-LOX platform, including potential applications in obesity and type 2 diabetes[4]